Polyphor Ltd. and Roche have entered into an exclusive worldwide license agreement to develop and commercialize Polyphor’s investigational macrocycle antibiotic, POL7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa. Polyphor will receive an upfront payment of CHF 35 million, as well as development, regulatory and commercial milestones of as much as CHF 465 million, and royalties on sales. Polyphor will retain the option to co-promote an inhaled formulation o...